Search research articles
Contact Us
Filters
Showing results (81-90 of 140) with videos related to
Page
of 14
Sort By:
Oncotarget
|
April 7, 2016
Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis
Ya-Ling Hsu, Jen-Yu Hung, Shin-Yi Chiang, et al.
Journal of Cellular Physiology
|
December 30, 2014
Chemokine (C-C Motif) Ligand 5 is Involved in Tumor-Associated Dendritic Cell-Mediated Colon Cancer Progression Through Non-Coding RNA MALAT-1
Jung-Yu Kan, Deng-Chyang Wu, Fang-Jung Yu, et al.
Scientific Reports
|
May 13, 2016
Corrigendum: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
Ming-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
Cancers
|
December 8, 2020
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
Hsiao-Ling Chen, Yu-Kang Tu, Hsiu-Mei Chang, et al.
Cancers
|
November 16, 2018
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, et al.
Carcinogenesis
|
August 20, 2013
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway
Chih-Hsin Kuo, Kuei-Fang Chen, Shah-Hwa Chou, et al.
Oncotargets and Therapy
|
April 5, 2016
Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
BMC Pharmacology & Toxicology
|
May 11, 2017
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
Chih-Jen Yang, Jen-Yu Hung, Ming-Ju Tsai, et al.
Scientific Reports
|
April 8, 2016
Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
Ming-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
The Kaohsiung Journal of Medical Sciences
|
October 10, 2022
Real-world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients
En-Chi Hsu, Kuan-Li Wu, Ying-Ming Tsai, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 140) with videos related to
Sort By:
Page
of 14
Oncotarget
|
April 7, 2016
Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis
Ya-Ling Hsu, Jen-Yu Hung, Shin-Yi Chiang, et al.
Journal of Cellular Physiology
|
December 30, 2014
Chemokine (C-C Motif) Ligand 5 is Involved in Tumor-Associated Dendritic Cell-Mediated Colon Cancer Progression Through Non-Coding RNA MALAT-1
Jung-Yu Kan, Deng-Chyang Wu, Fang-Jung Yu, et al.
Scientific Reports
|
May 13, 2016
Corrigendum: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
Ming-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
Cancers
|
December 8, 2020
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
Hsiao-Ling Chen, Yu-Kang Tu, Hsiu-Mei Chang, et al.
Cancers
|
November 16, 2018
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, et al.
Carcinogenesis
|
August 20, 2013
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway
Chih-Hsin Kuo, Kuei-Fang Chen, Shah-Hwa Chou, et al.
Oncotargets and Therapy
|
April 5, 2016
Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
BMC Pharmacology & Toxicology
|
May 11, 2017
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
Chih-Jen Yang, Jen-Yu Hung, Ming-Ju Tsai, et al.
Scientific Reports
|
April 8, 2016
Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
Ming-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
The Kaohsiung Journal of Medical Sciences
|
October 10, 2022
Real-world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients
En-Chi Hsu, Kuan-Li Wu, Ying-Ming Tsai, et al.
Page
of 14